GoodDoctorNet
Naeun Hospital Cardiology Ahn Tae-hun

Ahn Tae-hun

Naeun Hospital|Cardiology

Incheon Seo-gu

Last updated

관상동맥질환에 특화된 심장내과 교수로 임상과 중재시술의 노하우를 체계적으로 진료하는 신뢰로 입증된 전문가임

Book a visitWebsite

Medical opinions · Patient reviews0

No reviews yet.

If you've been treated by Ahn Tae-hun, be the first to leave a review.

Planning to see Ahn Tae-hun?

Save this doctor and find them again anytime on My page.

Ask other patients

If reviews don't answer your questions, ask patients and caregivers who have been there.

Patient stories: Cardiology

More
Browse the community

Hospital information

Hospitals
Naeun Hospital
Specialties
More Cardiology doctors
Address
201 Gajwa-ro, Seo-gu, Incheon
All doctors at Naeun Hospital

Education and career

Education

  • 고려대학교 의과대학 의학박사

Career

  • 고려대학교 의과대학 의학박사
  • 고려대학교 구로병원 내과 레지던트
  • 고려대학교 혜화병원 심장내과 전임의
  • 캐나다 몬트리올심장센타 연수
  • 가천대학교 길병원 심장내과 교수
  • 가천대학교 길병원 심장혈관센터장
  • 고려대학교 안암병원 순환기내과 임상교수
  • 중앙대학교 광명병원 순환기내과 임상진료교수
  • 대한심혈관중재학회(KSIC) 이사장
  • 대한심혈관합병증연구회(KCCC) 회장
  • 대한심장학회(KSC) 재무이사
  • KVIS (혈관중재술연구회) 회장
  • 대한심장학회(KSC) 회장
  • ENCORESEOUL 조직위원장
  • 현) 나은병원 심장혈관센터 원장
  • [논문]
  • 1. Lipid Burden and Efficacy of Preventive PCI of Vulnerable Atherosclerotic Coronary Plaques: Post Hoc Analysis From the PREVENT Trial. Circulation (IF 38.7), 2026
  • 2. Preventive percutaneous coronary intervention for non-flow-limiting vulnerable atherosclerotic coronary plaques in diabetes: the PREVENT trial.
  • EurHeart J. 2025 May 29:ehaf273.
  • 3. Prognostic Impact of CYP2C19 Genotypes on Long-Term Clinical Outcomes in Older Patients After Percutaneous Coronary Intervention. J Am Heart Assoc. 2024 May 21;13(10):e032248.
  • 4. EfficacyandSafetyofSirolimus-ElutingStentwithBiodegradablePolymerUltimaster™ in Unselected Korean Population: A Multicenter, Prospective, Observational Study From Korean Multicenter UltimasterRegistry. Korean Circ J. 2024 Apr 22.
  • 5. Prediction of longitudinal clinical outcomes after acute myocardial infarction using a dynamic machine learning algorithm. Front Cardiovasc Med. 2024 Apr 5;11:1340022
  • 6. Association of Age- and Body Mass Index-Stratified High On-Treatment Platelet Reactivity With Coronary Intervention Outcomes in East Asian Patients. J Am Heart Assoc. 2024 May 7;13(9):e031819
  • 7. Association between body mass index and three-year outcome of acute myocardial infarction. Sci Rep. 2024 Mar 1;14(1):365
  • 8. Preventivepercutaneouscoronaryinterventionversusoptimalmedicaltherapyaloneforthetreatmentofvulnerableatheroscleroticcoronaryplaques(PREVENT):amulticentre, open-label, randomisedcontrolled trial. Lancet. 2024 May 4;403(10438):1753-1765
  • 9. Preventive PCI or Medical Therapy Alone for Vulnerable Atherosclerotic Coronary Plaque: Rationale and Design of the Randomized, Controlled PREVENT Trial.
  • 10. Early Invasive Strategy Based on the Time of Symptom Onset of Non-ST-Segment Elevation Myocardial Infarction.
  • 11. Target Low-Density Lipoprotein-Cholesterol and Secondary Prevention for Patients with Acute Myocardial Infarction: A Korean Nationwide Cohort Study.
  • 12. A Comparative Analysis of Two Biolimus-Eluting Biodegradable Stents: Evaluation of the Equivalence of 6 Months Versus 12 Months of DAPT Following Biolimus-Eluting Stent Implantation in Acute Coronary Syndrome (EQUUS).
  • 13. Clinical Outcomes in Patients with Delayed Hospitalization for Non-ST Elevation Myocardial Infarction.
  • 14. LEFTY-PITX2 signaling pathway is critical for generation of mature and ventricular cardiac organoids in human pluripotent stem cell-derived cardiac mesoderm cells.
  • 15.Transplantation of 3D bio-printed cardiac mesh improves cardiac function and vessel formation via ANGPT1/Tie2 pathway in rats with acute myocardial infarction.
  • 16.Long-term outcomes after renal denervation in an Asian population: results from the Global SYMPLICITY Registry in South Korea (GSR Korea).
  • 17.Successful Long-term Patency of a Complicated Coronary Aneurysm at a Prior Coronary Branch Stent Treated with a Stent Graft and Dedicated Bifurcation Stent.
  • 18.Impact of genetic variants on clinical outcome after percutaneous coronary intervention in elderly patients.
  • 19.Efficacy and Safety of Dual-Drug-Eluting Stents for de Novo Coronary Lesions in South Korea—The Effect Trial.
  • 20.Clinically Significant Bleeding With Ticagrelor Versus Clopidogrel in Korean Patients With Acute Coronary Syndromes Intended for Invasive Management: A Randomized Clinical Trial.
  • 22.The effects of DPP4 inhibitors on the levels of plasma catecholamines and their metabolites in patients with type 2 diabetes.
  • 22. Ten-Year Outcomes of Stents versus Coronary-Artery Bypass Grafting for Left Main Coronary Artery Disease.
  • 23.A multicenter, randomized, and double-blind phase IV clinical trial to compare the efficacy and safety of fixed-dose combinations of amlodipine orotate/valsartan 5/160 mg versus valsartan/hydrochlorothiazide 160/12.5 mg in patients with essential hypertension uncontrolled by valsartan 160 mg monotherapy
  • 24.Randomized Prospective Comparison of Everolimus-Eluting vs. Sirolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention- 3-Year Clinical Outcomes of the EXCELLENT Randomized Trial
  • 25.Predictors and Long-Term Clinical Outcome of Longitudinal Stent Deformation: Insights From Pooled Analysis of Korean Multicenter Drug-Eluting Stent Cohort.
  • 26.Clinical Outcomes according to the Achievement of Target Low Density Lipoprotein-Cholesterol in Patients with Acute Myocardial Infarction
  • 27.Renal denervation for treatment of uncontrolled hypertension in an Asian population: results from the Global SYMPLICITY Registry in South Korea (GSR Korea).
  • 28.Intravascular ultrasound-guided retrograde percutaneous coronary intervention of a chronic total occlusion.
  • 29.Comparative effect on platelet function of a fixed-dose aspirin and clopidogrel combination versus separate formulations in patients with coronary artery disease: A phase IV, multicenter, prospective, 4-week non-inferiority trial.
  • 30.Trial of everolimus-eluting stents or bypass surgery for coronary disease.
  • 31.Everolimus-eluting XienceV/Promus versus Zotarolimus-eluting Resolute stent in patients with diabetes mellitus.
  • 32.Predictors of recovery of left ventricular systolic dysfunction after acute myocardial infarction: from the Korean acute myocardial infarction registry and Korean myocardial infarction registry.
  • 33.A comparison of two brands of clopidogrel in patients with drug-eluting stent implantation.
  • 34.Outcomes after unrestricted use of everolimus-eluting and sirolimus-eluting stents in routine clinical practice: a multicenter, prospective cohort study
  • 35. Repeated sudden cardiac death in coronary spasm: is IVUS helpful to decide treatment strategy
  • 36.Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) Randomized, Multicenter Study.
  • 37.Comparison of zotarolimus-eluting stents versus sirolimus-eluting stents versus paclitaxel-eluting stents for primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: results from the Korean MulticentreEndeavor (KOMER) acute myocardial infarction (AMI) trial.
  • 38.Everolimus-eluting versus sirolimus-eluting stents in patients undergoing percutaneous coronary intervention: the EXCELLENT (Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting) randomized trial.
  • 39. Long-Term Safety and Efficacy of Stenting Versus Coronary Artery Bypass Grafting for Unprotected Left Main Coronary Artery Disease 5-Year Results From the MAIN-COMPARE (Revascularization for Unprotected Left Main Coronary Artery Stenosis: Comparison of Percutaneous Coronary Angioplasty Versus Surgical Revascularization) Registry.
  • 40. Real-Time 3-Dimensional Echocardiography of the Heart 13 Years After Partial Left Ventriculectomy.
  • 41. Long-term safety and effectiveness of unprotected left main coronary stenting with drug-eluting stents compared with bare-metal stents (Revascularization for Unprotected Left Main Coronary Artery Stenosis: Comparison of Percutaneous Coronary Angioplasty Versus Surgical Revascularization Investigators).
  • 42. Stents versus coronary-artery bypass grafting for left main coronary artery disease
  • 43. Successful management of a resistant, focal calcified lesion following direct coronary stenting with a cutting balloon.
  • 44. Influence of stent expansion states on platelet deposition in an extracorporeal porcine arteriovenous shunt model using a multichannel perfusion channel
  • 45. Experience in high-speed rotational coronary atherectomy (Rotablator).
  • 46. Effectofdenopamineonleftventricularfunctioninpatientswithchronicheartfailure
  • 저서
  • 1. 심혈관중재매뉴얼(2016), 발행인, 저자, 대한심혈관중재학회(ISBN: 978-89-965763-3-4 93510)
  • 2. VIS Manual(2012), 대표저자, 군자출판사(ISBN 978-89-6278-565-4)
  • 3. KVIS Manual (2016). 저자, 혈관중재시술연구회(ISBN 978-89-97156-20-7)
  • 4. 관동맥완전폐색병변의 시술매뉴얼(2016), 저자, 군자출판사(ISBN 978-89-6278-494-7)
  • 5. 심혈관합병증 매뉴얼(2017), 저자, 대한심혈관합병증연구회(ISBN 978-89-97156-29-3)
  • 6. 심혈관중재매뉴얼 업데이트(2022), 저자, 대한심혈관중재학회(ISBN 978-89-965763-4-1 93510)
  • 7. 심근경색증 개정판(2022), 저자, 도서출판대한의학(ISBN 979-11-559022-0-2)

Academic societies

  • 중앙대학교 광명병원 순환기내과 임상진료교수 대한심혈관중재학회(KSIC) 이사장
  • 대한심혈관합병증연구회(KCCC) 회장
  • 대한심장학회(KSC) 재무이사
  • KVIS (혈관중재술연구회) 회장
  • 대한심장학회(KSC) 회장

FAQ

Where does Ahn Tae-hun see patients?
In Cardiology at Naeun Hospital. The hospital address is 201 Gajwa-ro, Seo-gu, Incheon.
What is Ahn Tae-hun's specialty?
Specialty: Cardiology.

Is any information wrong?

Let us know about changes to hospital, specialty, career and so on, and we'll update it after checking.